Shi‐Ming Lin

4.1k total citations · 1 hit paper
62 papers, 2.7k citations indexed

About

Shi‐Ming Lin is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Shi‐Ming Lin has authored 62 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hepatology, 42 papers in Epidemiology and 10 papers in Surgery. Recurrent topics in Shi‐Ming Lin's work include Liver Disease Diagnosis and Treatment (38 papers), Hepatocellular Carcinoma Treatment and Prognosis (36 papers) and Hepatitis B Virus Studies (17 papers). Shi‐Ming Lin is often cited by papers focused on Liver Disease Diagnosis and Treatment (38 papers), Hepatocellular Carcinoma Treatment and Prognosis (36 papers) and Hepatitis B Virus Studies (17 papers). Shi‐Ming Lin collaborates with scholars based in Taiwan, United States and China. Shi‐Ming Lin's co-authors include Chen‐Chun Lin, Yi‐Cheng Chen, I‐Shyan Sheen, Chao‐Wei Hsu, Chun‐Jung Lin, Yun‐Fan Liaw, Deng‐Yn Lin, Wei‐Ting Chen, Chun‐Jen Liu and Chuan–Mo Lee and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Shi‐Ming Lin

59 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

2024 93 citations Shi‐Ming Lin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shi‐Ming Lin Taiwan	22	2.0k	1.6k	403	373	275	62	2.7k
M. Colombo Italy	23	2.7k 1.4×	2.1k 1.3×	352 0.9×	413 1.1×	283 1.0×	70	3.4k
Tadashi Goto Japan	25	2.2k 1.1×	1.8k 1.1×	473 1.2×	517 1.4×	271 1.0×	46	3.2k
Hobyung Chung Japan	33	2.7k 1.4×	2.0k 1.2×	665 1.7×	334 0.9×	331 1.2×	77	3.3k
Manabu Morimoto Japan	33	2.1k 1.0×	1.2k 0.8×	770 1.9×	624 1.7×	636 2.3×	171	3.3k
Hyo‐Suk Lee South Korea	28	1.8k 0.9×	1.3k 0.8×	525 1.3×	290 0.8×	244 0.9×	82	2.4k
Shi‐Ming Lin Taiwan	23	1.7k 0.9×	1.5k 1.0×	169 0.4×	242 0.6×	127 0.5×	73	2.3k
Kohsaku Sakaguchi Japan	27	1.3k 0.7×	1.1k 0.7×	697 1.7×	361 1.0×	374 1.4×	92	2.5k
Deng‐Yn Lin Taiwan	26	2.3k 1.2×	2.2k 1.4×	535 1.3×	189 0.5×	269 1.0×	60	3.1k
Wen‐Juei Jeng Taiwan	26	1.8k 0.9×	1.6k 1.0×	165 0.4×	322 0.9×	339 1.2×	114	2.6k
Tatsuo Inoue Japan	29	1.7k 0.8×	1.1k 0.7×	385 1.0×	218 0.6×	250 0.9×	69	2.3k

Countries citing papers authored by Shi‐Ming Lin

Since Specialization

Citations

This map shows the geographic impact of Shi‐Ming Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi‐Ming Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi‐Ming Lin more than expected).

Fields of papers citing papers by Shi‐Ming Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shi‐Ming Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi‐Ming Lin. The network helps show where Shi‐Ming Lin may publish in the future.

Co-authorship network of co-authors of Shi‐Ming Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Shi‐Ming Lin. A scholar is included among the top collaborators of Shi‐Ming Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shi‐Ming Lin. Shi‐Ming Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Ming‐Shun, Wei‐Yu Kao, Shih–Jer Hsu, et al.. (2025). Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor Ablation. Liver Cancer. 15(1). 149–164.

Teng, Wei, et al.. (2025). Combination of Hepatic Arterial Infusion Chemotherapy with Tyrosine Kinase Inhibitor Provides Better Survival in Advanced Hepatocellular Carcinoma Patients. Journal of Hepatocellular Carcinoma. Volume 12. 1017–1029.

Teng, Wei, Eric Yi-Liang Shen, Bing‐Shen Huang, et al.. (2024). Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma. The Oncologist. 29(7). e922–e931. 6 indexed citations

Pan, Xian, Hanlu Wang, Shi‐Ming Lin, et al.. (2022). A Primary Extraskeletal Osteosarcoma of the Spleen: Rare Case Report. Frontiers in Oncology. 12. 892943–892943. 1 indexed citations

Chen, Chien‐Ming, Bing‐Shen Huang, Kuang‐Tse Pan, et al.. (2021). A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness. PLoS ONE. 16(3). e0249003–e0249003. 2 indexed citations

Teng, Wei, Wen‐Juei Jeng, Chien‐Hao Huang, et al.. (2020). Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. Advances in digestive medicine. 7(2). 83–92. 2 indexed citations

Lee, Chao‐Wei, et al.. (2019). Incorporation of biochemical factors for survival analysis of transarterial chemoembolization in patients with hepatocellular carcinoma: A retrospective cohort study. Journal of International Medical Research. 47(10). 4862–4871. 1 indexed citations

Jeng, Wen‐Juei, Chen‐Chun Lin, Wei‐Ting Chen, et al.. (2014). Adjuvant Therapy for Hepatocellular Carcinoma after Curative Treatment. Digestive Diseases. 32(6). 747–754. 14 indexed citations

Chuang, Ya‐Hui, Yahui Wang, Chih‐Feng Wu, et al.. (2014). Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma. PLoS ONE. 9(11). e95870–e95870. 60 indexed citations

10.

Hsu, Chao‐Wei, et al.. (2014). Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients. Biomedical Journal. 38(3). 250–250. 9 indexed citations

11.

Tsang, Ngan‐Ming, Shi‐Ming Lin, Deng‐Yn Lin, et al.. (2013). High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. Oncology Letters. 6(5). 1514–1520. 9 indexed citations

12.

Lin, Shi‐Ming. (2010). Local Ablation for Hepatocellular Carcinoma in Taiwan: Different Points between Japan, Asia and West. Oncology. 78(Suppl. 1). 102–106. 4 indexed citations

13.

Chen, Wei‐Ting, et al.. (2010). Delay in treatment of early‐stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program. Journal of Surgical Oncology. 103(2). 133–139. 20 indexed citations

14.

Tai, Dar‐In, Shi‐Ming Lin, I‐Shyan Sheen, et al.. (2009). Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time†. Hepatology. 49(6). 1859–1867. 135 indexed citations

15.

Lin, Chen‐Chun, Chun‐Jung Lin, Wei‐Ting Chen, et al.. (2007). Treatment of Hepatocellular Carcinoma Using Internally Cooled Electrodes. Oncology. 72(Suppl. 1). 76–82. 7 indexed citations

16.

Lin, Chen‐Chun, Chun‐Jung Lin, Chao‐Wei Hsu, et al.. (2007). Fine‐needle aspiration cytology to distinguish dysplasia from hepatocellular carcinoma with different grades. Journal of Gastroenterology and Hepatology. 23(7pt2). e146–52. 10 indexed citations

17.

Lin, Shi‐Ming, Chen‐Chun Lin, Wei‐Ting Chen, Yi‐Chen Chen, & Chao‐Wei Hsu. (2007). Radiofrequency Ablation for Hepatocellular Carcinoma: A Prospective Comparison of Four Radiofrequency Devices. Journal of Vascular and Interventional Radiology. 18(9). 1118–1125. 28 indexed citations

18.

Yeh, Chau‐Ting, Chao‐Wei Hsu, Ming‐Ling Chang, et al.. (2006). A Novel Ex Vivo Assay of Interferon‐Based Suppression, to Predict the Outcome of Antiviral Therapy for Hepatitis C. The Journal of Infectious Diseases. 193(10). 1365–1370. 3 indexed citations

19.

Lin, Shi‐Ming, Chun‐Jung Lin, Chen‐Chun Lin, Chao‐Wei Hsu, & Yi‐Cheng Chen. (2004). Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology. 127(6). 1714–1723. 439 indexed citations

20.

Liaw, Yun‐Fan, Rong‐Nan Chien, Shi‐Ming Lin, et al.. (1997). Response of Patients with Dual Hepatitis B Virus and C Virus Infection to Interferon Therapy. Journal of Interferon & Cytokine Research. 17(8). 449–452. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact